Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Net Assets
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares net assets. Based on the latest financial reports, Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) has net assets worth $9.58 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.84 Million) and total liabilities ($3.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HKPD net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.58 Million |
| % of Total Assets | 74.61% |
| Annual Growth Rate | 153.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 271.43 |
Net Assets of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
Net assets of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. This chart illustrates how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's net assets have evolved over time, based on quarterly financial data. See HKPD net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
The table below shows the annual net assets of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. For live market cap and overall valuation, see market value of Hong Kong Pharma Digital Technology Hold.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $9.58 Million | +92.06% |
| 2025-03-31 | $4.99 Million | +17.31% |
| 2024-03-31 | $4.25 Million | +626.82% |
| 2023-03-31 | $585.24K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 82.8% over the analyzed period, indicating profitable operations and earnings retention.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Net Assets Breakdown (March 2026)
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $368.09K | 3.84% |
| Common Stock | $23.50K | 0.25% |
| Other Comprehensive Income | $240.12K | 2.51% |
| Other Components | $8.95 Million | 93.41% |
| Total Equity | $9.58 Million | 100.00% |
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Competitors by Market Cap
The table below lists competitors of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
$5.96 Million |
|
Ashtead Technology Holdings PLC
LSE:AT
|
$5.96 Million |
|
Chewathai Public Company Limited
BK:CHEWA
|
$5.96 Million |
|
GACM Technologies Limited
NSE:GATECH
|
$5.96 Million |
|
Trinex Minerals Ltd
AU:TX3
|
$5.95 Million |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
$5.94 Million |
|
AMA Corp PLC
PA:ALAMA
|
$5.94 Million |
|
Filtronic
LSE:FTC
|
$5.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 4,989,769 to 9,583,123, a change of 4,593,354 (92.1%).
- Net loss of 1,135,963 reduced equity.
- Other comprehensive income increased equity by 229,303.
- Other factors increased equity by 5,500,014.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.14 Million | -11.85% |
| Other Comprehensive Income | $229.30K | +2.39% |
| Other Changes | $5.50 Million | +57.39% |
| Total Change | $- | 92.06% |
Book Value vs Market Value Analysis
This analysis compares Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.76x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 36.46x to 4.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-03-31 | $0.05 | $1.94 | x |
| 2024-03-31 | $0.58 | $1.94 | x |
| 2025-03-31 | $0.49 | $1.94 | x |
| 2026-03-31 | $0.41 | $1.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.46%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 1.34x
- Recent ROE (-11.85%) is below the historical average (47.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 170.56% | 7.95% | 3.69x | 5.82x | $939.67K |
| 2024 | 31.26% | 7.97% | 1.93x | 2.04x | $904.35K |
| 2025 | -0.54% | -0.13% | 2.16x | 1.89x | $-526.03K |
| 2026 | -11.85% | -8.46% | 1.05x | 1.34x | $-2.09 Million |
Industry Comparison
This section compares Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,695,658,318
- Average return on equity (ROE) among peers: -14.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) | $9.58 Million | 170.56% | 0.34x | $5.95 Million |
| Accendra Health Inc (ACH) | $1.03 Billion | 10.82% | 1.27x | $21.62 Million |
| Akso Health Group ADR (AHG) | $48.10 Million | -148.02% | 0.67x | $807.33 Million |
| Cardinal Health Inc (CAH) | $6.33 Billion | 21.53% | 5.47x | $43.01 Billion |
| Cencora Inc. (COR) | $4.34 Billion | 10.79% | 1.69x | $61.32 Billion |
| Cosmos Health Inc. (COSM) | $-1.75 Million | 0.00% | 0.00x | $15.91 Million |
| EDAP TMS SA (EDAP) | $33.82 Million | 0.54% | 0.51x | $154.80 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $741.21K | -42.90% | 4.10x | $143.05 Million |
| EDAP TMS S.A. (FOCL) | $56.92 Million | 1.45% | 0.54x | $154.24 Million |
| Henry Schein Inc (HSIC) | $3.43 Billion | 13.97% | 0.90x | $7.86 Billion |
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides valu… Read more